Results 61 to 70 of about 178,517 (322)

Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib

Expert Review of Clinical Pharmacology, 2021
Introduction: Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell lymphomas. Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part, for
C. Tam, Y. Ou, J. Trotman, Stephen Samuel Opat   +3 more
semanticscholar   +1 more source

Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction [PDF]

, 2019
Aims: Despite widespread use of dual antiplatelet therapy in acute myocardial infarction, there remains a residual risk of morbidity and mortality.
Ayton, Sarah, Bhatti, Maria, Bowles, Kristian, Flather, Marcus, Geisler, Tobias, Gollop, Nicholas D., Michail, Olga, Rushworth, Stuart, Ryding, Alisdair   +8 more
core   +1 more source

Role of Bruton′s Tyrosine Kinase in B Cell Development [PDF]

Journal of Immunology Research, 2001
X‐linked agammaglobulinemia (XLA) is one of the most frequent inherited immunodeficiency diseases in man and is characterized by an almost complete arrest of B cell differentiation at the pre‐B cell stage. The gene defective in XLA encodes the cytoplasmic signaling molecule Bruton′s tyrosine kinase (Btk).
Alex Maas, Rudolf W. Hendriks
openaire   +3 more sources

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate

eLife, 2015
Bruton's tyrosine kinase (Btk), a Tec-family tyrosine kinase, is essential for B-cell function. We present crystallographic and biochemical analyses of Btk, which together reveal molecular details of its autoinhibition and activation.
Qi Wang, Erik M Vogan, Laura M Nocka, Connor E Rosen, Julie A Zorn, Stephen C Harrison, John Kuriyan   +6 more
doaj   +1 more source

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

Frontiers in Immunology, 2017
Bruton’s tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell receptor signaling in the development and functioning of adaptive immunity.
A. Weber, Zsofia Bittner, Xiao Liu, Truong‐Minh Dang, M. Radsak, C. Brunner   +5 more
semanticscholar   +1 more source

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial

ACR Open Rheumatology, 2022
Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of evobrutinib in ...
D. Wallace, T. Dörner, D. Pisetsky, J. Sánchez-Guerrero, A. Patel, Dana Parsons-Rich, Claire Le Bolay, E. Drouin, A. Kao, H. Guehring, M. Dall'Era   +10 more
semanticscholar   +1 more source

Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.

PLoS ONE, 2019
BackgroundPharmacodynamic biomarkers are becoming increasingly valuable for assessing drug activity and target modulation in clinical trials. However, identifying quality biomarkers is challenging due to the increasing volume and heterogeneity of ...
Sonja Hatz, Scott Spangler, Andrew Bender, Matthew Studham, Philipp Haselmayer, Alix M B Lacoste, Van C Willis, Richard L Martin, Harsha Gurulingappa, Ulrich Betz   +9 more
doaj   +1 more source

Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis

Journal of Clinical Medicine, 2022
Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells ...
N. Garg, Elizabeth Padron, K. Rammohan, Courtney F Goodman   +3 more
semanticscholar   +1 more source

A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation [PDF]

, 2016
20siBruton's tyrosine kinase (BTK) is essential for B-cell proliferation/differentiation and it is generally believed that its expression and function are limited to bone marrow-derived cells.
Bonin, S, Bonomo, S, Cerrito, MG, Cialdella, A, Cicirelli, V, D’Amato, F, Ferri, GL, Giordano, F, Giovannoni, R, Grassilli, E, Helin, K, Ianzano, L, Lavitrano, M, Leone, BE, Masiero, L, Missaglia, C, Narloch, R, Noli, B, Pisano, F, Stanta, G   +19 more
core   +1 more source

Future therapeutic targets in rheumatoid arthritis? [PDF]

, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu, A Bilancio, A Del Prete, A Maas, AB Avci, AB Satterthwaite, AD Cook, AG Semb, AJ Fleetwood, AJ Fleetwood, AJ Mohamed, AL Bell, AL Cornish, AM Condliffe, AR Pettit, AW Lieshout van, B Ludewig, BF Nashed, BJ Jenkins, BZ Li, C Baerwald, C Meune, C Rommel, C Schindler, C Voigtlander, CA Martin, CJ Heijnen, CM Hilkens, CV Brenol, D Heijde van der, DH Solomon, DJ Rawlings, DL Bellinger, DM Nance, DS Lim, DT Patton, E Banham-Hall, E Clayton, E Feist, E Hirsch, E Martin, E Thomas, EB Lee, EC Tsark, EK Evans, F Berenbaum, F Bussolino, F Ramadani, FA Koopman, FA Koopman, FM Foster, G Hansen, GM Bell, GR Burmester, GR Burmester, H Evrengul, H Wang, Iain B. McInnes, IC Eijk van, IJ Elenkov, IK Campbell, J Askling, J Jang, J Kremer, JA Avina-Zubieta, JA Hamilton, JC Barrientos, JE Park, JM Kremer, JM Waldburger, JS Rawlings, JS Smolen, K Imada, K Okkenhaug, K Okkenhaug, K Okkenhaug, K Pavelka, K Reif, K Shuai, K Thiele, K Yamaoka, KL Winthrop, KP MacDonald, KS Nair, L Conti, L Jansson, L Senolt, L Zhang, L Zou, LC Cantley, LG Schipper, LJ Courtright, LV Borovikova, M Camps, M Dougados, M Field, M Gilliet, M Pesu, M Rosas-Ballina, M Skoberne, M Skoberne, M Soubrier, M Westman, MA Maanen van, MA Maanen van, MA Maanen van, MB Torchinsky, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Lebre, MC Lebre, MG Roncarolo, MJ Peters, MS Ahmed, MS Thomas, N Krishnamoorthy, N Sato, NJ Gullick, P Geborek, P Norman, P Sujobert, PC Heinrich, PC Taylor, Q Yang, R Fleischmann, R Fleischmann, RA Maldonado, RF Vollenhoven van, RH Straub, RM Buijs, RM Steinman, RM Steinman, S Hayer, S Kleinau, S Mukhopadhyay, S Mukhopadhyay, S Somersan, S Tsukada, SA Provan, ST Jou, T Leizer, T Li, Tommy Tsang Cheung, TR Radstake, WJ Jonge de, WN Khan, Y Ren, Y Xu, YP Goekoop-Ruiterman, Z Li, Z Pan   +154 more
core   +1 more source